Travere Therapeutics to Present at Upcoming Investor Conferences
25 nov. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 nov. 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
12 nov. 2024 16h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of...
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
07 nov. 2024 21h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a...
Travere Therapeutics Announces Proposed Public Offering of Common Stock
07 nov. 2024 16h01 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere Therapeutics to Present at Upcoming Investor Conferences
04 nov. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics Reports Third Quarter 2024 Financial Results
31 oct. 2024 07h00 HE
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
26 oct. 2024 07h01 HE
|
Travere Therapeutics, Inc.
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024.
Travere Therapeutics to Report Third Quarter 2024 Financial Results
21 oct. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the...
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
17 oct. 2024 07h01 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.